

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

Joshua Z. Press^{1*}, Alessandro De Luca^{2*}, Niki Boyd², Sean Young^{2,3}, Armelle Troussard², Yolanda Ridge³, Pardeep Kaurah³, Steve E. Kalloger⁴, Katherine A. Blood², Margaret Smith⁵, Paul T. Spellman⁶, Yucker Wang⁷, Dianne M. Miller⁸, Doug Horsman^{2,5}, Malek Faham⁷, C. Blake Gilks^{2,4§}, Joe Gray⁶, David G. Huntsman^{2,3,4}

¹Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, British Columbia, Canada; ²Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; ³Hereditary Cancer Program, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; ⁴Genetic Pathology Evaluation Centre of the Prostate Centre, Vancouver General Hospital, Vancouver, British Columbia, Canada; ⁵Molecular Genetics, The Royal Melbourne Hospital, Parkville, Australia, ⁶Life Sciences Division, Lawrence Berkeley National Laboratory, University of California, San Francisco, California, USA; ⁷Affymetrix Inc. 7300 Shoreline Blvd South, San Francisco, California, USA. ⁸Department of Gynecologic Oncology, University of British Columbia, Vancouver, British Columbia, Canada;

* These authors contributed equally to this work

§ Corresponding author

C. Blake Gilks MD FRCPC
Rm 1207, 1st Floor JPPN
Department of Pathology,
Vancouver General Hospital
910 West 10th Ave
Vancouver, B.C., Canada V5Z 4E3
Telephone: (604) 875-4901
Fax number: (604) 875-4797

Email addresses:

JZP: drjpress@telus.net
AD: alessandro.deluca@vch.ca
NB: nboyd@bccancer.bc.ca
SY: syoung@bccancer.bc.ca
AT: atroussa@bccrc.ca
YR: yridge@bccancer.bc.ca
PK: pkaurah@bccancer.bc.ca
SEK: skalloger@mac.com
KAB: kblood@bccrc.ca
MS: margie.smith@mh.org.au
PTS: ptspellman@lbl.gov
YW: Yucker_Wang@affymetrix.com
DMM: Dianne.Miller@vch.ca
DH: DHorsman@bccancer.bc.ca
MF: Malek_Faham@affymetrix.com
CBG: Blake.Gilks@vch.ca
JG: JWGray@lbl.gov
DGH: dhuntsma@bccancer.bc.ca

Background

Subclassification of ovarian carcinomas can be used to guide treatment and determine prognosis. Germline and somatic mutations, loss of heterozygosity (LOH), and epigenetic events such as promoter hypermethylation can lead to decreased expression of BRCA1/2 in ovarian cancers. The mechanism of BRCA1/2 loss is a potential method of subclassifying high grade serous carcinomas.

Methods

A consecutive series of 49 ovarian cancers was assessed for mutations status of BRCA1 and BRCA2, LOH at the BRCA1 and BRCA2 loci, methylation of the BRCA1 promoter, BRCA1, BRCA2, PTEN, and PIK3CA transcript levels, PIK3CA gene copy number, and BRCA1, p21, p53, and WT-1 immunohistochemistry.

Results

Eighteen (37%) of the ovarian carcinomas had germline or somatic BRCA1 mutations, or epigenetic loss of BRCA1. All of these tumours were high-grade serous or undifferentiated type. None of the endometrioid (n=5), clear cell (n=4), or low grade serous (n=2) carcinomas showed loss of BRCA1, whereas 47% of the 38 high-grade serous or undifferentiated carcinomas had loss of BRCA1. It was possible to distinguish high grade serous carcinomas with BRCA1 mutations from those with epigenetic BRCA1 loss: tumours with BRCA1 mutations typically had decreased PTEN mRNA levels while those with epigenetic loss of BRCA1 had copy number gain of PIK3CA. Overexpression of p53 with loss of p21 expression occurred significantly more frequently in high grade serous carcinomas with epigenetic loss of BRCA1, compared to high grade serous tumors without loss of BRCA1.

Conclusions

High grade serous carcinomas can be subclassified into three groups: BRCA1 loss (genetic), BRCA1 loss (epigenetic), and no BRCA1 loss. Tumors in these groups show distinct molecular alterations involving the PI3K/AKT and p53 pathways.

Background

Ovarian cancer is the most fatal gynecological cancer in North American women and the fifth most common cause of cancer death. Epithelial ovarian carcinomas (EOC) are subclassified according to tumor cell type and grade. These different subtypes of ovarian cancer are associated with different molecular characteristics: high grade serous cancers typically contain TP53 mutations [1, 2], low grade serous carcinomas often have RAS-RAF pathway activation and mutations in the KRAS and BRAF genes [3], low-grade endometrioid cancers are associated with mutations in the beta-catenin gene, CTNNB1 [4], and mucinous cancers frequently have mutations in KRAS [5]. Accurate subclassification of

ovarian cancers is essential because different subtypes of ovarian cancer respond differently to treatment and have different prognoses [6].

The majority of ovarian cancers are of serous subtype [7]. In a study of 220 ovarian carcinomas, over half were categorized as serous and over 90% of these serous ovarian cancers were high grade (grade II or III) [8]. High grade serous ovarian cancers are associated with BRCA1 or BRCA2 mutations [9-11]. BRCA1, located at 17q21 [12-14], and BRCA2, located at 13q12-q13 [15, 16] both encode tumor suppressors involved in repairing double-stranded DNA breaks and maintaining genomic stability [17-19]. Germline BRCA1 or BRCA2 mutations are present in 10% to 15% of all EOCs [20, 21]. Less commonly, EOCs contain somatic mutations in these genes [22]. In addition, aberrant expression of BRCA1 or BRCA2 may occur through loss of heterozygosity or, in the case of BRCA1, promoter hypermethylation [23-27]. Unlike breast cancer, where patients with germline mutations in BRCA1 or BRCA2 have cancers that are distinct from sporadic breast cancers on the basis of morphology or gene profiling [28-30], ovarian cancers with germline BRCA1 or BRCA2 mutations are indistinguishable from their sporadic counterparts [11, 23, 31-33]. High grade serous ovarian cancers that have functional BRCA1 or BRCA2 are currently not separable from high grade serous cancers that have loss of function of these proteins, based on routine histopathological examination. The challenge is to find methods to distinguish these subtypes of high grade serous cancers; this would stratify patients based on the underlying molecular events during oncogenesis, which is potentially highly relevant as these cancers may respond differently to treatment. This has recently been demonstrated in vitro: inhibitors of poly(ADP-ribose) polymerase (PARP1) were found to be able to target and kill cells deficient in either BRCA1 or BRCA2 [34, 35]. PARP1 binds to single-stranded DNA breaks, attracting proteins to repair DNA. Inhibition of PARP1 allows these single stranded breaks to progress to double stranded breaks through the resulting collapse of replication forks [34, 36]. The preferred double-strand break repair mechanism is homologous recombination which relies on the activity of BRCA1 and BRCA2. Thus, cells with loss of BRCA1 or BRCA2 function that are treated with PARP1 inhibitors are unable to repair DNA breaks, which leads to crisis and cell death.

We collected and analysed 49 consecutive ovarian tumor samples from consenting women diagnosed with invasive, non-mucinous EOC who were undergoing debulking surgery. We pathologically characterized these samples and analysed them for BRCA1 and BRCA2 mutations, loss of heterozygosity at both loci, mRNA levels of BRCA1 and BRCA2, expression of BRCA1, and BRCA1 promoter hypermethylation. In light of previous studies showing that promoter hypermethylation of BRCA2 is rarely if ever encountered in ovarian carcinoma [37-39], we did not undertake similar studies on the BRCA2 promoter. We then attempted to determine whether molecular profiles could be used to distinguish high grade serous cancers with BRCA1 mutations (germline or somatic), from high grade serous cancers with epigenetic loss of BRCA1 through

promoter hypermethylation, and high grade serous cancers without BRCA1 loss. We focused on the PI3K/AKT and p53 pathways which play important roles in ovarian cancer [40-43].

Methods

Recruitment and tumor samples. Between January 2004 and September 2005 all women undergoing primary debulking surgery for ovarian carcinoma were invited to participate in this study at the Vancouver General Hospital and British Columbia Cancer Agency in Vancouver, Canada. Women with mucinous and borderline tumors, and women who had received pre-operative chemotherapy were excluded. Pathology was reviewed by a single pathologist (CBG). Serous tumors were classified as low or high-grade as described previously [44]; all undifferentiated and clear cell carcinomas were considered high-grade. Endometrioid carcinomas were graded as grade 1, 2, or 3 according to the Silverberg grading system [45]. Ethical approval was obtained from the University of British Columbia Ethics Board (#H02-61375 and #H03-70606).

DNA and RNA extraction. Cancer tissue was split with part stored at -80 degrees and the facing tissue fixed in formalin and placed in paraffin blocks. H&E sections were reviewed to ensure samples consisted of $\geq 70\%$ tumor cells. DNA was extracted using the Puregene DNA Purification Kit (Gentra Systems, Inc, Wicklow, Ireland) according to manufacturer's instructions from whole blood (germline analysis) or tumor samples (somatic analysis). RNA was isolated with Trizol (Invitrogen, Carlsbad, CA) according to standard protocols.

Loss of heterozygosity analysis. Somatic loss of BRCA1/BRCA2 in tumor tissue was assessed for LOH using microsatellite markers for BRCA1 (D17S855 (60°C), D17S1185 (58°C), D17S1323 (56°C), and D17S1325 (56°C)) [46], and BRCA2 (D13S260 (60°C), D13S171 (50°C), D13S267 (53°C), D13S217 (55°C)) [9]. PCR products were electrophoresed in an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA), and analyzed with Genescan v3.1 software (Applied Biosystems, Foster City, CA). LOH was defined as a complete or partial ($\leq 50\%$) signal reduction of one allele in at least one marker. Microsatellite instability (MSI) was defined as the presence of novel alleles in the tumor DNA that were not present in normal DNA in at least one marker [47].

dHPLC mutation screening and mutation analysis. Screening for BRCA1/BRCA2 mutations was performed using denaturing high performance liquid chromatography (dHPLC). Tumor DNA was mixed in a 3:1 ratio with corresponding germline DNA for all tumors shown to possess LOH to ensure that LOH did not mask somatic mutations [48]. For example, with intratumoral LOH, and mutation of the remaining allele, dHPLC screening would give a false negative result. If the mutation is a germline mutation it will be picked up on dHPLC screening of germline DNA, however, a somatic mutation would be missed in both tumor and germline DNA without DNA mixing. PCR primers and conditions were developed by the Royal Melbourne Hospital (Australia) and are

available on request. PCR primers were used to amplify each exon of BRCA1 (24 exons) and BRCA2 (26 exons). All exons with abnormal dHPLC profiles were PCR amplified and bi-directionally sequenced to identify mutations using ABI BigDye terminator v3.1 cycle sequencing kit (Applied Biosystems, Foster City, CA) and an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA).

Multiplex Ligation-dependent Probe Amplification (MLPA) screening. For the identification of germline BRCA1 single and multiple exon deletions or duplications, multiplex ligation-dependent probe amplification analysis (MLPA) kits SALSA P002 BRCA1 and SALSA P087 BRCA1 (MRC Holland, Amsterdam, NL) were used according to manufacturer directions. A reduction or increase in RPA values to <0.7 or >1.3 was considered an indication of a deletion or a duplication, respectively [49].

BRCA1 and FANCF promoter hypermethylation analysis. The BRCA1 methylation status of each tumor was assessed using a technique similar to the MethyLight assay described previously [50]. Briefly, 500 ng of sample DNA was subjected to sodium bisulfite modification using the EZ DNA Methylation-Gold Kit, as recommended by the manufacturer (Zymo Research, Orange, CA). After bisulfite treatment, DNA was amplified using real-time PCR with oligonucleotide primers complementary to a region of the MYOD1 promoter that did not contain any CpG dinucleotides but did contain non-CpG cytosines to ascertain the amount of converted input templates in each sample. Hypermethylation of the BRCA1 promoter was then examined by real-time PCR amplification of bisulfite-modified DNA using oligonucleotide primers specific for a fully methylated bisulfite-converted portion of BRCA1 promoter such that only CpG islands that were methylated at every CpG dinucleotide interrogated by the primers and probes would be amplified and generate fluorescent signal. The sequences of the primers used to amplify and detect methylated BRCA1 promoter region were 5'-TAGAGTTT**CG**AGAGAC**CG**TTTGGTTT-3' (forward primer) and 5'-**CG**CTTTT**CCG**TACC**CGA**-3' (reverse primer). The primers for MYOD1 were 5'-CCA ACTCCA AATCCCCTC TCTAT-3' (forward primer) and 5'-TGATTAATTTAGATTGGGTTTAGAGAAGGA-3' (reverse primer). The amount of methylated DNA (PMR, percentage of methylated reference) [51] at the BRCA1 locus was calculated by dividing the BRCA1: MYOD1 ratio of a sample by the BRCA1: MYOD1 ratio of CpG methylated Jurkat genomic DNA (New England Biolabs, Ipswich, MA) and multiplying by 100. Reactions using CpG methylated Jurkat genomic DNA were used to normalize for any difference in amplification efficiencies between BRCA1 and MYOD1. The PMR serves as an index of the percentage of bisulfite converted input copies of DNA that are fully methylated at the primer hybridization sites. The PMR values obtained by MethyLight were dichotomized at 4 PMR for statistical purposes as described previously [51]. Samples containing 4 PMR or higher were designated as methylated, whereas samples containing less than 4 PMR were designated as unmethylated. It is important to note, however, that the PMR may be >1 if copies

of MYOD1 are deleted relative to the gene of interest, or copies of the gene of interest are gained relative to MYOD1 in any given sample. PCR experiments were carried out in a volume of 10 μ L with 384-well plates and an Applied Biosystems 7900HT Sequence Detector (Applied Biosystems, Foster City, CA). The fluorescence signal of the quantitative methylation-specific PCR was generated by SYBR Green I. Samples (10ng bisulfite-treated DNA) were run in triplicate containing 5 μ L SYBR Green Master Mix (Applied Biosystems, Foster City, CA) and 5 pmol of each forward and reverse primer. Bisulfite-converted CpG methylated Jurkat Genomic DNA (New England Biolabs, Ipswich, MA) served as a positive control and was used to generate a standard curve to quantify the amount of fully methylated promoters in each reaction. PCR amplification was done by means of the following procedure: 95°C for 15 minutes, followed by 40 cycles at 95°C for 15 seconds, 62°C for 1 minute. A subsequent dissociation curve analysis checked the specificity of products. FANCF promoter hypermethylation was assessed using a HpaII digest assay and methylation-specific PCR protocol previously reported by Taniguchi et al [52].

Real-time Q-RT-PCR. Extracted RNA was treated with DNase I (Invitrogen, Carlsbad, CA) prior to creating cDNA using random hexamer priming and MMLV reverse transcriptase (Invitrogen, Carlsbad, CA). Applied Biosystems Taqman primer/probe kits (Hs00173233_m1 (BRCA1), Hs00609060_m1 (BRCA2), Hs01920652_s1 (PTEN), Hs00907966_m1(PIK3CA)) were used to quantify mRNA expression levels using real-time qRT-PCR [37] and an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Relative gene expression quantification was calculated according to the comparative Ct method using human 18S ribosomal RNA (Applied Biosystems, Foster City, CA) and commercial RNA controls (Stratagene, La Jolla, CA). Relative quantification was determined as follows: $2^{-(\Delta C_t \text{ sample} - \Delta C_t \text{ calibrator})}$. Ratios (tumor relative gene expression:average of all tumors) less than 0.7 or greater than 1.3 for were scored as decreased or increased mRNA expression, respectively.

Immunohistochemistry. The BRCA1 antibody Ab-1 (Oncogene, 1:50 dilution) was used and antigen retrieval was performed in 1x EDTA buffer (pH 8.0) by microwaving for 2 minutes, and then boiling in a waterbath for 30 minutes. Endogenous peroxide activity was blocked with 3% hydrogen peroxide and then sections were incubated with 2.5% normal horse blocking serum. Following incubation with the primary antibody, the Vector Laboratories (Burlingame, CA) ImmPRESS kit was used according to the manufacturer's recommendations to visualize antibody complexes. Nuclear staining was assessed by CBG, who was blinded to all other BRCA analysis. Tumors were considered BRCA1 positive if greater than 1% of tumor nuclei showed staining. IHC was also performed with the following panel of previously validated antibodies using a Ventana (Tucson, AZ) automated immunostainer: p21 (Neomarkers, Fremont, CA, clone DCS-60.2, 1:100 dilution), p53 (Dako, Carpinteria, CA, clone DO-7, 1:400 dilution),

and WT-1 (Dako, Carpinteria, CA, clone 6F-H2, 1:50 dilution). BRCA1 IHC was done on whole sections, while other IHC markers were assessed using sections from a tissue microarray constructed with two 0.6 mm cores per case.

Molecular Inversion Probe (MIP) Copy Number

The MIP copy number assay was done as described previously [53] with some modifications. Specifically, the current protocol is a modification of the Targeted Genotyping protocol commercialized by Affymetrix [54]. Test DNA samples were diluted to 16 ng/μl. Molecular inversion probes were annealed to DNA by mixing 4.7 μl of DNA (75 ng total), 0.75 μl of Buffer A, 1.1 μl of the 53K molecular inversion probe pool (200 amol/ μl/probe) and 0.045 μl of Enzyme A in a 384-well plate on ice. The reaction was incubated for 4 min at 20°C, 5 min at 95°C, then overnight at 58°C. Following annealing, 13 μl of Buffer A and 1.25 μl of Gap Fill Enzyme mix were added to each reaction and 9 μl of reaction volume was transferred to each of two wells in a 96-well plate. Molecular inversion probes were circularized with 4 μl of dNTP mix at 58°C for 10 min. Linear probes and genomic DNA were eliminated by addition of 4 μl of Exo Mix and incubation at 37°C for 15 min, followed by universal primer amplification for 18 cycles (20 sec at 95°C, 40 sec at 64°C, and 10 sec at 72°C). For labelling reactions, the product was further amplified for 10 cycles using labelled primers, then subjected to cleavage by HY Digest Mix at 37°C for 2 hours. The cleaved MIP products were mixed with Hybridization Cocktail, denatured, and hybridized to 70K Universal Taq arrays at 39°C for 16 h (two arrays per sample). The overnight hybridized arrays were washed on a GeneChip® Fluidics Station FS450 and stained by SAPE at 5ng/ml (Invitrogen).

Copy number estimation was obtained from the hybridization signals as previously described [55], with the following modifications: the color-separation step was omitted as the single color readout on two arrays prevented the spectral overlap that occurs with multi-color readouts, and Langmuir correction was performed instead of linear calibration of allele signals [56]. Copy numbers over 3.0 were considered amplification events and copy numbers below 1.5 were considered deletion events.

Data analysis. Epigenetic BRCA1 loss was defined as having promoter hypermethylation accompanied by either low relative BRCA1 mRNA expression, negative BRCA1 IHC, or both low BRCA1 mRNA and negative BRCA1 IHC. Tumors without promoter hypermethylation and with positive BRCA1 IHC were not considered to have BRCA1 loss. Tumors with negative BRCA1 IHC without promoter hypermethylation were considered equivocal for BRCA1 loss. A chi-squared test or Fisher exact test was used to analyze categorical variables (MIP copy number, IHC) and a student's t-test was used to analyze continuous variables (RNA expression).

Results

Representative results of analysis for BRCA1 mutations, BRCA1 loss of heterozygosity, and BRCA1 promoter hypermethylation are shown in Figure 1.

BRCA1 findings for all tumors are presented as Figure 2. Based on these results, ovarian cancers were divided into six groups: (1) BRCA1 mutations, (2) BRCA1 epigenetic loss, (3) equivocal for BRCA1 loss, (4) high grade serous/undifferentiated cancers without BRCA1 loss, (5) BRCA2 mutations, and (6) clear cell, endometrioid, and low grade serous cancers.

Nine of the samples (18%) carried BRCA1 mutations (eight germline, one somatic) and three samples (6%) had BRCA2 mutations (two germline, one somatic). No intragenic deletions in BRCA1 were detected by MLPA analysis. Nine samples (18%) were found to have loss of BRCA1 due to epigenetic events; these samples all had hypermethylation of the BRCA1 promoter accompanied by decreased BRCA1 mRNA levels (relative qRT-PCR expression <0.7) and/or lack (less than 1% of tumour nuclei) of BRCA1 immunohistochemical staining. Five samples (10%), which did not carry BRCA1 mutations, were all unmethylated at the BRCA1 promoter; these were classified as “equivocal for BRCA1 loss” because they fulfilled two of the following criteria: loss of heterozygosity (LOH) at the BRCA1 locus, decreased BRCA1 mRNA levels, or lack of BRCA1 immunohistochemical staining. All samples ($n=26$) with BRCA1 or BRCA2 mutations, epigenetic loss of BRCA1, or classified as equivocal for BRCA1 loss were of high grade serous/undifferentiated type. Twelve tumors (24%) of high grade serous/undifferentiated type did not have BRCA1 mutations or epigenetic loss, or BRCA2 mutations. Thus, considering only the 38 high grade serous/undifferentiated tumours in our study, 18 (18/38, 47%) had loss of BRCA1 either through genetic or epigenetic events, three (3/38, 8%) carried germline or somatic BRCA2 mutations, 12 (12/38, 32%) had preservation of BRCA1 expression and no mutations in BRCA1 or BRCA2, and the remaining five tumors (5/38, 13%) were equivocal for BRCA1 loss and did not have BRCA2 mutations. FANCF promoter hypermethylation was not observed in any of these cases.

The remaining 11 tumour samples (22%) (i.e. those cases other than the high grade serous/undifferentiated carcinomas) were either clear cell (4), endometrioid (5), or low grade serous type (2). These samples were all negative for BRCA1 or BRCA2 mutations, negative for BRCA1 promoter hypermethylation, and positive for BRCA1 expression as determined by immunohistochemistry.

We further analyzed the 35 high grade serous/undifferentiated tumour samples that did not contain BRCA2 mutations using a combination of MIP copy number, qRT-PCR, and immunohistochemistry in order to determine whether these different groups could be classified according to specific molecular features other than BRCA1 or BRCA2 abnormalities (Figure 3). The number of tumors with BRCA2 mutations ($n=3$) was considered too small for meaningful further analysis

of this subset and was therefore excluded. Thirty-one of these tumours were positive for WT1 expression by immunohistochemistry, a marker of serous cell type in EOC, thus confirming our histopathological subclassification [57]; all clear cell and endometrioid cancers in this study were negative for WT1 expression (data not shown). Currently, the group of high grade serous/undifferentiated carcinoma is indivisible based on morphology or routinely used diagnostic molecular markers. We specifically focused on the PI3K/AKT and p53 pathways which are known to be important in EOC. We found that those tumours with BRCA1 loss through genetic events differed according to several parameters from tumours with loss of BRCA1 due to epigenetic events. Most striking were differences in PIK3CA copy number as determined by the MIP copy number assay. While none of the BRCA1 mutation positive cases demonstrated an increased PIK3CA copy number almost all (7/8) of the samples with epigenetic loss of BRCA1 had increased copy number at the PIK3CA locus. The PIK3CA copy number increases were low level (mean amplification ratio 2.7, range 1.7-4.9), and in all but one case amplification of PIK3CA was associated with amplification of the entire chromosomal arm. PIK3CA mRNA levels were assessed using qRT-PCR and relative mRNA levels were found to correlate with copy number ratios ($p=0.02$). Specificity of MIP copy number data was verified by assessing c-myc amplification; while PIK3CA copy number appeared to be selectively increased in specific subgroups, amplification at the c-myc locus was observed at similar frequencies in all subgroups. Interestingly, decreased PTEN mRNA levels observed in cancers with BRCA1 mutations and increased PIK3CA copy number in cancers with epigenetic loss of BRCA1 were almost mutually exclusive (Figure 4). These events represent two separate mechanisms of activation of the canonical PI3K/AKT pathway.

We further compared those tumors with either genetic or epigenetic loss of BRCA1 with high grade serous cancers without evidence of BRCA1 loss (Table 1). Representative immunohistochemical images for BRCA1, p53, and p21 from all three of these groups are shown in Figure 5. MIP copy number analysis of the nine tumours that had BRCA1 mutations showed that there was no loss or gain at the region of chromosome 3 that contains the gene for PIK3CA and only four (44%) samples stained positively for p53. By contrast, of the samples that had loss of BRCA1 due to epigenetic events, seven of eight samples (88%) had an increased PIK3CA copy number, and eight of nine samples (89%) stained positively for p53. In addition, high grade serous cancers without BRCA1 loss had low frequencies of positive p53 staining (4/12, 33%) and increased PIK3CA copy number (3/12, 25%), similar to cancers with BRCA1 mutations but distinct from cancers with epigenetic loss of BRCA1. In two cases (#366 and #217) we were unable to obtain MIP copy number data. It was noted that positive p53 staining was most often accompanied by negative p21 staining. The expression of p21 is increased in response to p53. High level overexpression of p53 correlates with p53 mutations and loss of function and would be anticipated to be associated with decreased p21 expression, as we observed. This p53+/p21-

immunophenotype was significantly more common in tumors with BRCA1 epigenetic loss than in tumors without BRCA1 loss (Table 1).

Discussion

The sub-classification of ovarian carcinomas, which is based on histopathological subtype and grade, is unable to adequately predict prognosis or response to treatment. Administration of adjuvant platinum/taxane chemotherapy is the standard treatment for ovarian carcinoma following debulking surgery [58]. Approximately 70% of advanced-stage ovarian carcinomas, however, will recur with development, ultimately of platinum-resistant disease [59]. A comparison of clinical outcomes between ovarian cancer patients with BRCA1 promoter hypermethylation to patients with BRCA1 mutations and wild-type BRCA1 genes demonstrated that patients with BRCA1 promoter hypermethylation had significantly shorter survival times compared to the other two groups [60]. Ovarian carcinomas in patients with BRCA1, in contrast are associated with a favourable prognosis [23, 61]. This data suggests that different abnormalities in BRCA1 could be associated with different clinical outcomes and possibly distinct alterations in other underlying molecular abnormalities. For example, the colon cancers from patients with inherited mutations in DNA mismatch repair genes differ from sporadic cancers with microsatellite instability due to hypermethylation of the *MLH1* promoters [62], with respect to age of onset of disease, pathology, and molecular alterations [63].

We evaluated 49 ovarian carcinomas and categorized them according to pathology and BRCA1 and BRCA2 status. We further evaluated 35 high grade serous/undifferentiated tumours that we divided into four groups based on BRCA1 mutation status, expression, and promoter hypermethylation. We observed increased positive p53 immunohistochemical staining, which correlated with negative p21 immunostaining, in cancers with epigenetic BRCA1 loss, compared to cancers with BRCA1 mutations and high grade serous/undifferentiated cancers without BRCA1 loss. p53 is a tumor suppressor that is involved in the progression of many cancers and is the most commonly mutated gene in ovarian carcinomas [37]. Typically, mutations in p53 result in accumulation of p53 in the nucleus and the majority of cases with abundant p53 detectable by immunohistochemistry are p53 mutant [64, 65]. The p53 protein is an important mediator of apoptosis resulting from DNA damage, stress, or chemotherapy [66]. p21 is a downstream effector of the cell cycle arrest function of p53 and is upregulated at the transcriptional level by wildtype but not mutated p53 [67]. At present, p53 mutation status or expression is not used to guide clinical decisions [68]. We have observed that p53 overexpression correlates, as expected, with loss of p21 expression. Furthermore the phenotype of p53 overexpression with loss of p21 is significantly more common in high grade serous/undifferentiated tumors with epigenetic loss of BRCA1 compared to high grade serous/undifferentiated tumors without loss of BRCA1.

In addition, we found that ovarian carcinomas with loss of BRCA1 through genetic events and those with BRCA1 loss through epigenetic events both have activation of the PI3K/AKT pathway, though the mechanism of activation is different. PI3K phosphorylates phosphatidylinositol lipids in response to activation by receptor tyrosine kinases [69]. Its activity has been linked to proliferation, differentiation, cell adhesion, apoptosis, tumorigenesis, and angiogenesis [70]. PTEN is a phosphatase whose activity counters PI3K. The serine/threonine kinase AKT is a downstream target of PI3K [71] and the activity of one of its isoforms, AKT1, is elevated in ovarian carcinomas [72]. Both decreased PTEN levels and amplification of PIK3CA lead to increased phosphorylation of AKT and it has been previously shown that ovarian cancers often have alterations in PI3K and PTEN [73-75]. This is the first study, however, to report that decreased PTEN expression levels are associated with ovarian carcinomas carrying BRCA1 mutations while increased PIK3CA copy number is associated with ovarian carcinomas with epigenetic loss of BRCA1. It has been previously demonstrated in breast cancer and glioblastoma that PIK3CA mutations and PTEN loss are virtually mutually exclusive, suggesting that abrogation of just one of these proteins is sufficient for tumorigenesis [76,77]. We observe a similar result in our ovarian serous cancer samples; it is likely that deregulation of this pathway, while critical for tumorigenesis, can be accomplished through alteration of a single key molecule at which point selective pressure is relieved for altering other proteins involved in this signalling pathway. Our findings in serous ovarian carcinoma, and the previous results from studies of breast cancer and glioblastoma, are in contrast to ovarian carcinoma of endometrioid type [78], and endometrial cancer [79,80], where PTEN mutations and PIK3CA mutations frequently co-exist. This is yet another example of molecular events during the genesis of ovarian cancer that show tumor cell type specificity, and reinforces the need to consider cell type differences in studies of ovarian cancer pathogenesis.

We would expect that cancers with activation of the PI3K/AKT pathway may not respond well to common chemotherapy, as overexpression of activated AKT decreases apoptosis induced by paclitaxel in ovarian cancer cells [81] and introduction of the catalytic subunit of PI3K into ovarian cancer cells causes resistance to paclitaxel [82]. In addition, the PI3K inhibitor, LY294002, has been shown to decrease growth of ovarian carcinoma and ascites formation in mouse xenograft models of ovarian carcinoma [83]. As therapies continue to be developed that target the PI3K/AKT pathway, it will be essential to understand the molecular alterations that are affecting this pathway in different types of ovarian carcinomas.

The need for meaningful sub-classification of ovarian carcinoma is critical for improving the treatment and prognosis of patients. Though sub-classification may be done based on BRCA1 genetic testing, this cannot be done in a timely fashion such that it could be used to guide therapy of patients newly diagnosed with ovarian cancer. This is extremely important as patients must embark on

therapy shortly after diagnosis. In addition, as new therapeutics are developed, rapid identification of appropriate patients will be necessary for clinical trials. Our results demonstrate that it may be possible to categorize patients based on rapid molecular tests to identify patients who are likely to harbour BRCA1 mutations. Negative BRCA1 immunohistochemical staining, decreased BRCA1 mRNA, lack of PI3K amplification, and absence of BRCA1 promoter hypermethylation is an example of a molecular profile that could be used to identify these patients. This would also allow more cost effective and efficient mutation screening in patients presenting with ovarian carcinoma.

Conclusions

This is the first study to comprehensively examine data from detailed analysis of BRCA1 and BRCA2 abnormalities in ovarian cancer. Results presented here demonstrate that high grade serous/undifferentiated carcinomas can be subclassified based on the underlying BRCA abnormalities. Such clinically relevant subclassification is critical for developing specific treatments for ovarian cancer patients which will lead to improved prognosis and management of disease.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JZP participated in the study design and coordination, patient recruitment, sample collection and handling, molecular analysis, immunohistochemical analysis, and drafting of the manuscript. AD participated in the tumor analysis, molecular analysis, and drafting of the manuscript. NB contributed to drafting of the manuscript. SY participated in the BRCA1/2 germline mutational analysis. AT participated in drafting of the manuscript. YR and PK are clinical genetic counsellors who were involved in recruitment of patients. SEK was involved in tissue banking and statistical analysis. KAB contributed to molecular analysis. MS contributed to design and validation of BRCA1 and BRCA2 primers for dHPLC mutation analysis. PTS and YK contributed to the MIP copy number assay experiments. DMM obtained consent for tissue banking and surgically collected tumor samples. DH was involved in BRCA1/2 germline mutation analysis and drafting of the manuscript. MF participated in the MIP copy number assay experiments. CBG was involved in study concept and design, pathological analysis, data analysis and interpretation, and drafting of the manuscript. JG participated in whole genome copy number analysis using MIP probes. DGH participated in study concept and design, data analysis and interpretation, and drafting of the manuscript. All authors have read and approved the final version of the manuscript.

Acknowledgements

This work was funded by the National Cancer Institute of Canada (# 017051), the Michael Smith Foundation for Health Research Unit Grant (#INRUA006045), and an NCI SPORE grant (#P50 CA83639). N. Boyd and S. Kalloger are supported in part by OvCaRe. D. Huntsman and A. De Luca are supported by the Michael Smith Foundation for Health Research.

References

1. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, Parkin DE, Haites NE: **p53 mutation is a common genetic event in ovarian carcinoma.** *Cancer Res* 1993, **53**:2128-2132.
2. Soslow RA, Shen PU, Chung MH, Isacson C: **Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.** *Int J Gynecol Pathol* 1998, **17**:129-134.
3. Singer G, Oldt R, 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih le M: **Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.** *J Natl Cancer Inst* 2003, **95**:484-486.
4. Saegusa M, Hashimura M, Yoshida T, Okayasu I: **beta- Catenin mutations and aberrant nuclear expression during endometrial tumorigenesis.** *Br J Cancer* 2001, **84**:209-217.
5. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM: **K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.** *Am J Pathol* 1991, **139**:777-785.
6. Bell DA: **Origins and molecular pathology of ovarian cancer.** *Mod Pathol* 2005, **18 Suppl 2**:S19-32.
7. Seidman JD, Kurman RJ: **Pathology of ovarian carcinoma.** *Hematol Oncol Clin North Am* 2003, **17**:909-925, vii.
8. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM: **The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin.** *Int J Gynecol Pathol* 2004, **23**:41-44.
9. Gras E, Cortes J, Diez O, Alonso C, Matias-Guiu X, Baiget M, Prat J: **Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.** *Cancer* 2001, **92**:787-795.
10. Koul A, Malander S, Loman N, Pejovic T, Heim S, Willen R, Johannsson O, Olsson H, Ridderheim M, Borg AA: **BRCA1 and BRCA2 mutations in ovarian cancer: Covariation with specific cytogenetic features.** *Int J Gynecol Cancer* 2000, **10**:289-295.
11. Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH, Ryan A, Menko FH, Kenemans P, Jacobs IJ: **Histopathologic**

- features of genetically determined ovarian cancer.** *Int J Gynecol Pathol* 2002, **21**:407-411.
12. Albertsen HM, Smith SA, Mazoyer S, Fujimoto E, Stevens J, Williams B, Rodriguez P, Cropp CS, Slijepcevic P, Carlson M *et al*: **A physical map and candidate genes in the BRCA1 region on chromosome 17q12-21.** *Nat Genet* 1994, **7**:472-479.
 13. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: **Linkage of early-onset familial breast cancer to chromosome 17q21.** *Science* 1990, **250**:1684-1689.
 14. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W *et al*: **A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.** *Science* 1994, **266**:66-71.
 15. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D *et al*: **The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds.** *Nat Genet* 1996, **12**:333-337.
 16. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, Nguyen K, Seal S, Tran T, Averill D *et al*: **Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.** *Science* 1994, **265**:2088-2090.
 17. Jasin M: **Homologous repair of DNA damage and tumorigenesis: the BRCA connection.** *Oncogene* 2002, **21**:8981-8993.
 18. Venkitaraman AR: **Cancer susceptibility and the functions of BRCA1 and BRCA2.** *Cell* 2002, **108**:171-182.
 19. Boulton SJ: **Cellular functions of the BRCA tumour-suppressor proteins.** *Biochem Soc Trans* 2006, **34**:633-645.
 20. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K *et al*: **BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.** *Cancer* 2005, **104**:2807-2816.
 21. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, Jack E, Vesprini DJ, Kuperstein G, Abrahamson JL *et al*: **Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.** *Am J Hum Genet* 2001, **68**:700-710.
 22. Merajver SD, Pham TM, Caduff RF, Chen M, Poy EL, Cooney KA, Weber BL, Collins FS, Johnston C, Frank TS: **Somatic mutations in the BRCA1 gene in sporadic ovarian tumours.** *Nat Genet* 1995, **9**:439-443.
 23. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY: **Improved survival in women with BRCA-associated ovarian carcinoma.** *Cancer* 2003, **97**:2187-2195.
 24. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA *et al*: **Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors.** *J Natl Cancer Inst* 2000, **92**:564-569.

25. Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y *et al*: **BRCA1 mutations in primary breast and ovarian carcinomas**. *Science* 1994, **266**:120-122.
26. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA: **BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study**. *Int J Gynecol Cancer* 2006, **16 Suppl 1**:166-171.
27. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D *et al*: **Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential**. *Cancer* 2006, **107**:299-308.
28. Armes JE, Venter DJ: **The pathology of inherited breast cancer**. *Pathology* 2002, **34**:309-314.
29. Goffin JR, Chappuis PO, Begin LR, Wong N, Brunet JS, Hamel N, Paradis AJ, Boyd J, Foulkes WD: **Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data**. *Cancer* 2003, **97**:527-536.
30. Lakhani SR, Van De Vijver MJ, Jacquemier J, Anderson TJ, Osin PP, McGuffog L, Easton DF: **The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2**. *J Clin Oncol* 2002, **20**:2310-2318.
31. Boyd J, Sonoda Y, Federici MG, Bogomolny F, Rhei E, Maresco DL, Saigo PE, Almadrones LA, Barakat RR, Brown CL *et al*: **Clinicopathologic features of BRCA-linked and sporadic ovarian cancer**. *Jama* 2000, **283**:2260-2265.
32. Werness BA, Ramus SJ, DiCioccio RA, Whittemore AS, Garlinghouse-Jones K, Oakley-Girvan I, Tsukada Y, Harrington P, Gayther SA, Ponder BA *et al*: **Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry**. *Int J Gynecol Pathol* 2004, **23**:29-34.
33. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET: **Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers**. *J Natl Cancer Inst* 2002, **94**:990-1000.
34. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T: **Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase**. *Nature* 2005, **434**:913-917.
35. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C *et al*: **Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy**. *Nature* 2005, **434**:917-921.

36. Turner N, Tutt A, Ashworth A: **Hallmarks of 'BRCAness' in sporadic cancers.** *Nat Rev Cancer* 2004, **4**:814-819.
37. Chan KY, Ozcelik H, Cheung AN, Ngan HY, Khoo US: **Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.** *Cancer Res* 2002, **62**:4151-4156.
38. Collins N, Wooster R, Stratton MR. **Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers.** *Br J Cancer.* 1997;**76**:1150-6.
39. Gras E, Cortes J, Diez O, Alonso C, Matias-Guiu X, Baiget M, Prat J. **Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors.** *Cancer.* 2001;**92**:787-95.
40. Aunoble B, Sanches R, Didier E, Bignon YJ: **Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).** *Int J Oncol* 2000, **16**:567-576.
41. Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V *et al*: **Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.** *Int J Cancer* 1995, **64**:280-285.
42. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, Tsichlis PN, Testa JR: **AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas.** *Proc Natl Acad Sci U S A* 1992, **89**:9267-9271.
43. Yuan ZQ, Feldman RI, Sun M, Olashaw NE, Coppola D, Sussman GE, Shelley SA, Nicosia SV, Cheng JQ: **Inhibition of JNK by cellular stress- and tumor necrosis factor alpha-induced AKT2 through activation of the NF kappa B pathway in human epithelial Cells.** *J Biol Chem* 2002, **277**:29973-29982.
44. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG: **Grading ovarian serous carcinoma using a two-tier system.** *Am J Surg Pathol* 2004, **28**:496-504.
45. Silverberg SG: **Histopathologic grading of ovarian carcinoma: a review and proposal.** *Int J Gynecol Pathol* 2000, **19**:7-15.
46. Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, Katsuyama Y, Konishi I: **Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.** *J Pathol* 2004, **202**:215-223.
47. Regitnig P, Moser R, Thalhammer M, Luschin-Ebengreuth G, Ploner F, Papadi H, Tsybrovskyy O, Lax SF: **Microsatellite analysis of breast carcinoma and corresponding local recurrences.** *J Pathol* 2002, **198**:190-197.
48. Liu W, Smith DI, Rechtzigel KJ, Thibodeau SN, James CD: **Denaturing high performance liquid chromatography (DHPLC) used in the**

- detection of germline and somatic mutations.** *Nucleic Acids Res* 1998, **26**:1396-1400.
49. Hogervorst FB, Nederlof PM, Gille JJ, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Welsem T, van Spaendonk R, Menko FH *et al*: **Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method.** *Cancer Res* 2003, **63**:1449-1453.
 50. Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV *et al*: **Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma.** *Cancer Res* 2000, **60**:5021-5026.
 51. Eads CA, Lord RV, Wickramasinghe K, Long TI, Kurumboor SK, Bernstein L, Peters JH, DeMeester SR, DeMeester TR, Skinner KA *et al*: **Epigenetic patterns in the progression of esophageal adenocarcinoma.** *Cancer Res* 2001, **61**:3410-3418.
 52. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD: **Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors.** *Nat Med* 2003, **9**:568-574.
 53. Hardenbol P, Yu F, Belmont J, Mackenzie J, Bruckner C, Brundage T, Boudreau A, Chow S, Eberle J, Erbilgin A *et al*: **Highly multiplexed molecular inversion probe genotyping: over 10,000 targeted SNPs genotyped in a single tube assay.** *Genome Res* 2005, **15**:269-275.
 54. http://www.affymetrix.com/products/application/targeted_genotyping.affx
 55. Wang Y, Moorhead M, Karlin-Neumann G, Falkowski M, Chen C, Siddiqui F, Davis RW, Willis TD, Faham M: **Allele quantification using molecular inversion probes (MIP).** *Nucleic Acids Res* 2005, **33**:e183.
 56. Burden CJ, Pittelkow YE, Wilson SR: **Statistical analysis of adsorption models for oligonucleotide microarrays.** *Stat Appl Genet Mol Biol* 2004, **3**:Article35.
 57. Al-Hussaini M, Stockman A, Foster H, McCluggage WG: WT-1 assists in distinguishing between ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. *Histopathology* 2004, **44**:109-115.
 58. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ: **Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.** *J Clin Oncol* 2002, **20**:1248-1259.
 59. Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, Alberts D: **Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.** *J Clin Oncol* 2003, **21**:2460-2465.
 60. Chiang JW, Karlan BY, Cass L, Baldwin RL: **BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.** *Gynecol Oncol* 2006, **101**:403-410.

61. Majdak EJ, Debniak J, Milczek T, Cornelisse CJ, Devilee P, Emerich J, Jassem J, De Bock GH: **Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma.** *Cancer* 2005, **104**:1004-1012.
62. McGivern A, Wynter CV, Whitehall VL, Kambara T, Spring KJ, Walsh MD, Barker MA, Arnold S, Simms LA, Leggett BA *et al*: **Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer.** *Fam Cancer* 2004, **3**:101-107.
63. Jass JR, Walsh MD, Barker M, Simms LA, Young J, Leggett BA: **Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability.** *Eur J Cancer* 2002, **38**:858-866.
64. Sasano H, Goukon Y, Nishihira T, Nagura H: **In situ hybridization and immunohistochemistry of p53 tumor suppressor gene in human esophageal carcinoma.** *Am J Pathol* 1992, **141**:545-550.
65. Esrig D, Spruck CH, 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S, Chen SC, Skinner DG, Jones PA, Cote RJ: **p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer.** *Am J Pathol* 1993, **143**:1389-1397.
66. Roos WP, Kaina B: **DNA damage-induced cell death by apoptosis.** *Trends Mol Med* 2006, **12**:440-450.
67. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B: **WAF1, a potential mediator of p53 tumor suppression.** *Cell* 1993, **75**:817-825.
68. Agarwal R, Kaye SB: **Expression profiling and individualisation of treatment for ovarian cancer.** *Curr Opin Pharmacol* 2006, **6**:345-349.
69. Chen HC, Guan JL: **Association of focal adhesion kinase with its potential substrate phosphatidylinositol 3-kinase.** *Proc Natl Acad Sci U S A* 1994, **91**:10148-10152.
70. Roymans D, Slegers H: **Phosphatidylinositol 3-kinases in tumor progression.** *Eur J Biochem* 2001, **268**:487-498.
71. Jiang BH, Aoki M, Zheng JZ, Li J, Vogt PK: **Myogenic signaling of phosphatidylinositol 3-kinase requires the serine-threonine kinase Akt/protein kinase B.** *Proc Natl Acad Sci U S A* 1999, **96**:2077-2081.
72. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV *et al*: **AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells.** *Am J Pathol* 2001, **159**:431-437.
73. Schondorf T, Gohring UJ, Roth G, Middel I, Becker M, Moser N, Valter MM, Hoopmann M: **Time to progression is dependent on the expression of the tumour suppressor PTEN in ovarian cancer patients.** *Eur J Clin Invest* 2003, **33**:256-260.
74. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW: **PIK3CA is implicated as an oncogene in ovarian cancer.** *Nat Genet* 1999, **21**:99-102.

75. Yokomizo A, Tindall DJ, Hartmann L, Jenkins RB, Smith DI, Liu W: **Mutation analysis of the putative tumor suppressor PTEN/MMAC1 in human ovarian cancer.** *Int J Oncol* 1998, **13**:101-105.
76. Saal LH, Holm K, Maurer M, Memeo L, Su T, Wang X, Yu JS, Malmstrom PO, Mansukhani M, Enoksson J *et al*: **PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.** *Cancer Res* 2005, **65**:2554-2559.
77. Broderick DK, Di C, Parrett TJ, et al. **Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas.** *Cancer Res* 2004, **64**:5048-5050.
78. Wu r, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon E, Cho KR. **Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt-catenin and PICK/Pten signaling pathways.** *Cancer Cell* 2007, **11**:321-333.
79. Oda K, Stokoe D, Taketani Y, McCormick F. **High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma.** *Cancer Res* 2005, **65**:10669-10673.
80. Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon G, Baker SJ, Ellenson LH. **PIK3CA and PTEN mutations in endometrioid carcinoma and complex atypical hyperplasia.** *Clin Cancer Res* 2006, **12**:5932-5935.
81. Page C, Lin HJ, Jin Y, Castle VP, Nunez G, Huang M, Lin J: **Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.** *Anticancer Res* 2000, **20**:407-416.
82. Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB: **Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.** *Cancer Res* 2002, **62**:1087-1092.
83. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB: **In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).** *Clin Cancer Res* 2000, **6**:880-886.

Figures

Figure 1: Assessment of BRCA1 loss (A) Mutation screening showing the abnormal denaturing high performance liquid chromatography profile corresponding to the 1351delAT mutation in tumor 223. The single blue line represents the electropherogram from a normal control, while the purple line represents the abnormal profile formed by the mutated exon 11c in tumor 223. (B) Direct DNA sequencing demonstrating the 185delAG mutation in tumor 283. Only the mutant allele is seen in the tumor because LOH is present. (C-E) Loss of heterozygosity (LOH) analysis using BRCA1-associated microsatellite markers visualized on an ABI Prism 3100 Genetic Analyzer, where LOH is defined as

>50% decrease in area under the curve when germline DNA (upper tracing) and tumor DNA (lower tracing) are compared. (C) The lack of LOH in tumor 240 demonstrated using microsatellite marker D17S1185, (D) LOH in tumor 283 demonstrated using microsatellite marker D17S855. (E) Microsatellite instability demonstrated in tumor 156 using microsatellite marker D17S1185. (F, G, H, and I) Methylation analysis of BRCA1 gene using fluorescence-based, quantitative, real-time PCR (TaqMan) using SYBR Green 1 as detection method. Two sets of primers, designed specifically for bisulfite converted DNA, were used: a methylated set for the BRCA1 gene and a reference set (MYOD1) to control for input DNA. Specificity of the reactions for methylated DNA were confirmed separately using human genomic DNA (unmethylated; F) and CpG methylated Jurkat genomic DNA (methylated; G), respectively. H and I show representative examples of results from assessment of BRCA1 loss through promoter hypermethylation. Tumor 178 shows only unmethylated BRCA1 promoter, while tumor 345 shows evidence of BRCA1 promoter hypermethylation.

Figure 2: Summary of BRCA1 abnormalities and associated features:

Pathology refers to the tumor histopathology. Serous or Ser = serous carcinoma; Undiff = undifferentiated carcinoma; HG = high-grade; LG = low-grade; Clear cell = clear cell carcinoma; Endo = endometrioid carcinoma; G1 = grade 1; G2 = grade 2; G3 = grade 3. **BRCA1 Status:** Mut = mutation; G = germline; S = somatic; N = no mutations. LOH = loss of heterozygosity where LOH indicates that loss of heterozygosity is present, NO indicates that loss of heterozygosity is not present, and MSI indicates that microsatellite instability is present in the tumor. Meth refers to BRCA1 promoter hypermethylation. Tumors containing $\geq 4\%$ fully methylated molecules are designated as methylated (M) and are highlighted in orange, whereas tumors containing $< 4\%$ are designated as unmethylated (U). RNA refers to relative RNA expression compared to the average RNA expression in all samples, where the average RNA expression = 1.0. Tumors with relative RNA expression < 0.7 are highlighted in aqua as showing BRCA1/BRCA2 loss. IHC refers to BRCA1 immunohistochemistry; (+) indicates tumors with $> 1\%$ of nuclei stained positive for BRCA1, (-) indicates tumors with $< 1\%$ of nuclei positive. N/A indicates that the data is not available for technical reasons.

Figure 3: Summary of analysis of high grade (HG) serous/undifferentiated ovarian tumors: MIP copy number results are shown for c-myc and PIK3CA loci. MIP copy number values over 3.0 are highlighted and correspond to amplification. Relative mRNA levels for PIK3CA and PTEN were assessed using qRT-PCR; levels over 1.3 (highlighted in green) are considered elevated and levels below 0.7 (highlighted in aqua) indicate decreased transcript levels. Associated immunohistochemical markers p21, p53, and WT-1 refer to immunohistochemical staining results. Scoring of immunostaining was done as follows: p21: 0 = $< 5\%$ nuclei positive and 1 = $> 5\%$ of nuclei positive. p53: 0 = $< 50\%$ nuclei positive and 1 = $> 50\%$ of nuclei positive. WT1: 0 = $< 5\%$ nuclei

positive, 1 = 5-50% nuclei positive, and 2 = >50% nuclei positive. N/A indicates that the data is not available for technical reasons.

Figure 4: Correlation between decreased PTEN mRNA levels and amplification at the PIK3CA locus: Relative PTEN mRNA levels as determined by qRT-PCR are plotted along the X-axis and PIK3CA MIP copy number results are plotted along the Y-axis for high grade serous ovarian tumors with BRCA1 mutations (open circles) and high grade serous ovarian tumors with epigenetic loss of BRCA1 (filled triangles). MIP copy number values over 3.0 indicate amplification.

Figure 5: Immunohistochemistry results: Representative immunohistochemistry results for high grade serous ovarian tumors with BRCA1 mutations (tumor #327, top row), with epigenetic loss of BRCA1 (tumor #332, middle row), and without loss of BRCA1 (tumor #372, bottom row). Immunohistochemical staining is shown for BRCA1 (left column), p53 (middle column) and p21 (right column).

Tables

Table 1: Comparison of PIK3 CA amplification or p53/p21 protein expression in High Grade Serous Ovarian Tumours


Group	PIK3CA amplification (MIP copy number)	p53/p21 IHC		
		+/-	+/+, -/-	-/+
BRCA1 loss through mutation	0/9 ⁺	4/9	2/9	3/9
BRCA1 epigenetic loss	7/8 ⁺	8/9 ^{**}	1/9	0/9
No BRCA1 loss	3/11 ⁺	3/12 ^{**}	5/12	4/12

* p = 0.02 for pairwise comparison based on Bonferroni-Holmes corrected Fisher exact test


** p = 0.03 for pairwise comparison based on Bonferroni-Holmes corrected Fisher exact test

+ p = 0.001 for threeway comparison based on Bonferroni-Holmes corrected Fisher exact test


(A)




(B)




(C)




(D)




(E)




(F)




(G)



(H)



(I)



#	Pathology	BRCA1 status					Classification
		Mut	LOH	Meth	RNA	IHC	
186	Ser/Undiff-HG	G	NO	U	0.44	—	BRCA1 loss through germline or somatic mutation
223	Serous - HG	G	MSI	U	0.14	—	
329	Serous - HG	G	LOH	U	0.02	—	
293	Serous - HG	G	LOH	U	0.65	—	
283	Serous - HG	G	LOH	U	3.1	—	
239	Serous - HG	G	LOH	U	0.16	—	
336	Ser/Undiff-HG	G	LOH	U	0.1	—	
327	Serous - HG	G	LOH	U	0.04	—	
379	Serous - HG	S	LOH	U	0.07	—	High grade carcinoma with epigenetic BRCA1 loss
217	Serous - HG	N	LOH	M	0.08	—	
330	Serous - HG	N	LOH	M	0.07	—	
332	Serous - HG	N	LOH	M	0.08	—	
388	Serous - HG	N	LOH	M	0.67	—	
363	Serous - HG	N	LOH	M	0.27	—	
161	Ser/Undiff-HG	N	LOH	M	0.09	—	
344	Serous - HG	N	LOH/MSI	M	0.3	—	
345	Serous - HG	N	MSI	M	0.41	+	Equivocal BRCA1 loss
384	Serous - HG	N	LOH	M	0.15	—	
201	Ser/Undiff-HG	N	LOH	U	1.87	—	
178	Serous - HG	N	LOH	U	0.42	—	
229	Serous - HG	N	LOH	N/A	0.19	—	
309	Serous - HG	N	NO	U	0.56	—	High grade carcinoma without BRCA1 loss
394	Serous - HG	N	LOH	U	0.89	—	
195	Serous - HG	N	N.A.	U	1.53	+	
236	Serous - HG	N	LOH	U	1.69	+	
280	Ser/Undiff-HG	N	LOH	U	3.11	+	
172	Serous - HG	N	LOH	U	2.21	+	
254	Serous - HG	N	LOH	U	0.48	+	
319	Serous - HG	N	LOH	U	0.62	+	
372	Serous - HG	N	LOH	U	2.02	+	
208	Undiff - HG	N	LOH	U	0.81	+	
273	Undiff - HG	N	LOH	U	1.54	+	
240	Undiff - HG	N	NO	U	0.41	+	
297	Serous - HG	N	NO	U	1.766	+	
366	Serous - HG	N	LOH	U	2.25	+	BRCA2 loss through mutation
163	Serous - HG	N	LOH	U	2.08	+	
305	Serous - HG	N	LOH	U	1.54	—	
212	Serous - HG	N	LOH	U	1.22	+	clear cell, endometriod, and low grade serous (No BRCA1 loss)
198	Clear cell	N	NO	U	1.55	+	
213	Clear cell	N	NO	U	2.9	+	
219	Clear cell	N	NO	U	0.58	+	
392	Clear cell	N	NO	U	1.51	+	
242	Endo - G2	N	NO	U	1.02	+	
281	Endo - G2	N	NO	U	1.35	+	
334	Endo - G1	N	NO	U	1.18	+	
156	Endo - G2	N	MSI	U	1.42	+	
343	Endo - G2	N	NO	U	0.27	+	
221	Serous - LG	N	LOH	U	1.46	+	
324	Serous - LG	N	NO	U	0.5	+	

#	Pathology	MIP COPY NUMBER		qRT-PCR		IHC			Classification
		C-MYC	PIK3CA	PIK3CA	PTEN	p53	p21	WT1	
186	Ser/Undiff-HG	2.4	2.7	1.68	0.58	0	0	2	BRCA1 loss through germline or somatic mutation
223	Serous - HG	5.8	2.5	0.48	0.32	1	0	2	
329	Serous - HG	3.4	2.0	0.1	0.11	1	0	2	
293	Serous - HG	2.6	2.4	1.05	0.94	0	1	2	
283	Serous - HG	3.3	2.0	0.62	0.55	1	0	2	
239	Serous - HG	3.0	2.3	0.33	0.45	0	0	0	
336	Ser/Undiff-HG	9.6	1.7	0.12	0.06	0	1	0	
327	Serous - HG	2.0	2.4	0.07	0.1	1	0	2	
379	Serous - HG	3.6	2.0	0.68	0.33	0	1	2	High grade carcinoma with epigenetic BRCA1 loss
217	Serous - HG	NA	NA	1.18	1.14	1	0	2	
330	Serous - HG	2.9	3.2	0.42	0.52	1	0	2	
332	Serous - HG	5.1	4.9	2.08	0.99	1	0	2	
388	Serous - HG	3.2	2.9	1.12	0.67	1	0	2	
363	Serous - HG	5.0	3.6	3.31	1.37	0	0	2	
161	Ser/Undiff-HG	2.5	3.0	1.02	0.39	1	0	2	
344	Serous - HG	3.0	3.3	1.6	0.89	1	0	2	
345	Serous - HG	5.8	3.9	2.02	0.39	1	0	2	Equivocal BRCA1 loss
384	Serous - HG	3.8	3.2	2.53	2.69	1	0	2	
201	Ser/Undiff-HG	2.7	2.9	0.75	2.65	1	0	2	
178	Serous - HG	5.7	2.8	2.64	0.75	1	0	2	
229	Serous - HG	4.2	3.1	0.29	0.32	1	0	2	
309	Serous - HG	1.9	2.2	1.18	2.2	0	0	2	High grade carcinoma without BRCA1 loss
394	Serous - HG	2.4	2.2	1.05	0.72	0	0	2	
195	Serous - HG	3.9	2.1	1.09	2.71	1	0	2	
236	Serous - HG	3.3	2.7	1.22	0.94	0	0	2	
280	Ser/Undiff-HG	7.7	3.1	2.18	0.66	1	1	2	
172	Serous - HG	2.1	1.8	0.86	0.74	0	1	0	
254	Serous - HG	2.9	2.0	0.38	0.58	0	0	2	
319	Serous - HG	3.2	1.9	0.4	0.75	0	1	2	
372	Serous - HG	4.0	3.6	2.89	1.36	0	1	1	
208	Undiff - HG	4.9	3.7	1.03	1.06	0	0	2	
273	Undiff - HG	3.9	1.9	0.33	0.39	1	0	1	
240	Undiff - HG	2.8	2.2	0.36	0.47	0	1	0	
297	Serous - HG	2.0	2.2	2.06	3.14	0	0	2	
366	Serous - HG	NA	NA	0.83	0.66	1	0	2	

PI3K CA Array CGH

